Article thumbnail

Crossing borders to bind proteins—a new concept in protein recognition based on the conjugation of small organic molecules or short peptides to polypeptides from a designed set

By Lars Baltzer


A new concept for protein recognition and binding is highlighted. The conjugation of small organic molecules or short peptides to polypeptides from a designed set provides binder molecules that bind proteins with high affinities, and with selectivities that are equal to those of antibodies. The small organic molecules or peptides need to bind the protein targets but only with modest affinities and selectivities, because conjugation to the polypeptides results in molecules with dramatically improved binder performance. The polypeptides are selected from a set of only sixteen sequences designed to bind, in principle, any protein. The small number of polypeptides used to prepare high-affinity binders contrasts sharply with the huge libraries used in binder technologies based on selection or immunization. Also, unlike antibodies and engineered proteins, the polypeptides have unordered three-dimensional structures and adapt to the proteins to which they bind. Binder molecules for the C-reactive protein, human carbonic anhydrase II, acetylcholine esterase, thymidine kinase 1, phosphorylated proteins, the D-dimer, and a number of antibodies are used as examples to demonstrate that affinities are achieved that are higher than those of the small molecules or peptides by as much as four orders of magnitude. Evaluation by pull-down experiments and ELISA-based tests in human serum show selectivities to be equal to those of antibodies. Small organic molecules and peptides are readily available from pools of endogenous ligands, enzyme substrates, inhibitors or products, from screened small molecule libraries, from phage display, and from mRNA display. The technology is an alternative to established binder concepts for applications in drug development, diagnostics, medical imaging, and protein separation

Topics: Review
Publisher: Springer-Verlag
OAI identifier:
Provided by: PubMed Central

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.

Suggested articles


  1. (1999). A Guide to Enzyme Catalysis and Protein
  2. (2010). A new assay design for clinical diagnostics based on alternative recognition elements.
  3. (2004). A versatile polypeptide platform for integrated recognition and reporting—affinity arrays for protein-ligand interaction analysis.
  4. (1997). An integrated system for optical biomolecular interaction analysis.
  5. (2000). Antibodies in diagnostics - from immunoassays to protein chips.
  6. (2006). Aptamers come of age – at last.
  7. (2000). Biology and relevance of C-reactive protein in cardiovascular and renal disease.
  8. (2011). Boosting the affinity of a tetrapeptide by polypeptide conjugation in the molecular recognition of the D-dimer. submitted for publication
  9. (2005). C-reactive protein comes of age.
  10. Casini A,MonteroJ-L,Scozzafava A,Supuran CT (2003) Carbonic Anhydrase Inhibitors. Inhibition of Cytosolic Isozymes I and II and Transmembrane, Tumor-Associated Isozyme IX with Sulfamates Including EMATE Also Acting as Steroid Sulfatase Inhibitors.
  11. (2009). Characterization of Ca2+ and phosphocholine interactions with C-reactive protein.
  12. (2010). Clinical Relevance of Thymidine Kinase for the Diagnosis, Therapy Monitoring and Prognosis of Non-οperable Lung Cancer.
  13. (2009). Colorimetric Protein Sensing by Controlled Assembly of Gold Nanoparticles Functionalized with Synthetic Receptors.
  14. (2005). Cooperative binding of human Carbonic Anhydrase II by functionalized folded polypeptide receptors.
  15. (2009). D-dimer antigen: current concepts and future prospects.
  16. (2007). DARPins: a true alternative to antibodies. Curr Opin Drug Discov Dev 10:153–159
  17. (2001). De novo design of proteins – What are the rules? Chem Rev 101:3153–3163
  18. (2010). Design of an optimized scaffold for affibody molecules.
  19. (1995). Design, Synthesis and Solution Structure of a Helix–Loop–Helix Dimer–a Template for the Rational Design of Catalytically Active Polypeptides.
  20. (2011). Designed protein binders in combination with nano crystalline diamond for use in high-sensitivity biosensors.
  21. (2002). Designed, folded polypeptide scaffolds that Crossing borders to bind proteins 1663combine key biosensing events of recognition and reporting.
  22. (2004). Designed, functionalized helix–loop–helix motifs that bind human Carbonic Anhydrase II – a new class of synthetic receptor molecules.
  23. (2002). Designing peptide receptor agonists and antagonists.
  24. (2001). Engineered antibodies take center stage.
  25. (2008). Function and structure of inherently disordered proteins.
  26. (2007). Handbook of Therapeutic Antibodies.
  27. (2009). Hohlbaum AM, Skerra A
  28. (1948). Inhibition of carbonic anhydrase by sulphonamides.
  29. (1970). Kinetics of complex formation between human carbonic anhydrases and aromatic sulfonamides.
  30. (2009). Label-free determination of protein-ligand binding constants using mass spectrometry and validation using surface plasmon resonance and isothermal titration calorimetry.
  31. (2001). mRNA display: Diversity matters during in vitro selection.
  32. (2002). NMR-Based Screening with Competition Water−Ligand Observed via Gradient Spectroscopy Experiments: Detection of High-Affinity Ligands.
  33. (2005). Novel „digital-style“ rapid test simultaneously detecting heart attack and predicting cardiovascular disease risk.
  34. (2007). Particulate platform for bioluminescent immunosensing.
  35. PastorekJ,IsolaJ,MiettinenM(2010)CarbonicanhydraseII.Anovel biomarker for gastrointestinal stromal tumors.
  36. (2007). Polypeptide conjugate binders for protein recognition.
  37. (2011). Polypeptide conjugate binders that discriminate between two isoforms of human Carbonic Anhydrase in human blood.
  38. (2011). Powerful protein binders from designed polypeptides and small organic molecules–a general concept for protein recognition. Angew Chem Int Ed 50:1823–1827
  39. (1996). Protein Phosphorylation.
  40. (2006). SAR by NMR: putting the pieces together.
  41. (2009). Single-chain antibodies as diagnostic tools and therapeutic agents.
  42. (1980). Studies on synthetic peptides that bind to fibrinogen and prevent fibrin polymerization. Structural requirements, number of binding sites, and species differences.
  43. (2010). Synthesis of C-11 linked active ester derivatives of vitamin D-3 and their conjugations to 42-residue helix loop helix peptides.
  44. (2008). The exploration of macrocycles for drug discovery—an underexploited structural class. Nat Rev Drug Discov 7:608–624
  45. (2011). The molecular recognition of phosphorylated proteins by designed polypeptides conjugated to a small molecule that binds phosphate.
  46. (1999). The physiological structure of human C-reactive protein and its complex with phosphocholine.
  47. (2003). Vision impairment therapies.